Join Growin Stock Community!

Qiagen n.v.QGEN.US Overview

US StockHealthcare
(No presentation for QGEN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

QGEN AI Insights

QGEN Overall Performance

QGEN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

QGEN Recent Performance

-3.09%

Qiagen n.v.

0.05%

Avg of Sector

-0.31%

S&P500

QGEN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

QGEN Key Information

QGEN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

QGEN Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Price of QGEN

QGEN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

QGEN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.06
PE Ratio (TTM)
24.41
Forward PE
19.85
PS Ratio (TTM)
4.91
PB Ratio
2.68
Price-to-FCF
22.19
METRIC
VALUE
vs. INDUSTRY
Gross Margin
62.18%
Net Margin
20.33%
Revenue Growth (YoY)
5.65%
Profit Growth (YoY)
34.34%
3-Year Revenue Growth
2.76%
3-Year Profit Growth
0.81%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
2.06
PE Ratio (TTM)
24.41
Forward PE
19.85
PS Ratio (TTM)
4.91
PB Ratio
2.68
Price-to-FCF
22.19
Gross Margin
62.18%
Net Margin
20.33%
Revenue Growth (YoY)
5.65%
Profit Growth (YoY)
34.34%
3-Year Revenue Growth
2.76%
3-Year Profit Growth
0.81%

  • When is QGEN's latest earnings report released?

    The most recent financial report for Qiagen n.v. (QGEN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating QGEN's short-term business performance and financial health. For the latest updates on QGEN's earnings releases, visit this page regularly.

  • Where does QGEN fall in the P/E River chart?

    According to historical valuation range analysis, Qiagen n.v. (QGEN)'s current price-to-earnings (P/E) ratio is 26.1, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of QGEN?

    According to the latest financial report, Qiagen n.v. (QGEN) reported an Operating Profit of 99.44M with an Operating Margin of 18.4% this period, representing a decline of 16.51% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is QGEN's revenue growth?

    In the latest financial report, Qiagen n.v. (QGEN) announced revenue of 540.42M, with a Year-Over-Year growth rate of 3.69%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does QGEN have?

    At the end of the period, Qiagen n.v. (QGEN) held Total Cash and Cash Equivalents of 839.01M, accounting for 0.13 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does QGEN go with three margins increasing?

    In the latest report, Qiagen n.v. (QGEN) achieved the “three margins increasing” benchmark, with a gross margin of 60.2%%, operating margin of 18.4%%, and net margin of 20%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess QGEN's profit trajectory and future growth potential.

  • Is QGEN's EPS continuing to grow?

    According to the past four quarterly reports, Qiagen n.v. (QGEN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.49. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of QGEN?

    Qiagen n.v. (QGEN)'s Free Cash Flow (FCF) for the period is 117.22M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 17.92% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of QGEN?

    The latest valuation data shows Qiagen n.v. (QGEN) has a Price-To-Earnings (PE) ratio of 26.1 and a Price/Earnings-To-Growth (PEG) ratio of -1.71. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.